GleamWall
中文EN

CNTX Context Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1842952 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-66.0%
TTM EPS YoY-91.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-84.3%
ROA-75.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets15.1%
Debt / equity0.00x
Current ratio6.59x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-17.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$31.86M$22.70M
SG&A expense$7.85M$7.22M
Operating income-$39.70M-$29.92M
Income tax$0$0
Net income-$36.12M-$26.73M
EBITDA-$39.69M-$29.91M
EPS (basic)-0.38-0.46
EPS (diluted)-0.38-0.46
Weighted avg. shares (diluted)95.19M58.42M
Balance sheet
Cash & equivalents$66.00M$94.43M
Current assets$68.35M$97.90M
PP&E, net$29,656$11,959
Total assets$68.49M$98.13M
Current liabilities$8.02M$2.75M
Total liabilities$8.02M$2.86M
Shareholders' equity$60.47M$95.27M
Shares outstanding91.88M89.70M
Cash flow statement
Operating cash flow-$26.39M-$14.56M
Capital expenditure$33,948$7,316
Free cash flow-$26.42M-$14.56M
Investing cash flow-$2.03M-$14.76M
Financing cash flow-$15,268$109.29M
Depreciation & amortization$16,251$10,881
Stock-based compensation$1.33M$841,867

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.